[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100147860":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":7,"locations":13,"responsibleParty":26,"collaborators":7,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":7,"eligibilityCriteria":34,"healthyVolunteers":30,"sex":35,"minAge":36,"maxAge":37,"enrollmentInfo":38,"targetDuration":7,"studyType":41,"phases":7,"briefSummary":42,"conditions":43,"keywords":45,"overallStatus":51,"whyStopped":7,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},{"fullName":5,"class":6},"Merck KGaA, Darmstadt, Germany","INDUSTRY",null,[9],{"name":10,"affiliation":11,"role":12},"Michalis Arvanitis, MD, MSc","Merck A.E. Hellas,Greece, an affiliate of MerckKGaA, Darmstadt, Germany","STUDY_DIRECTOR",[14],{"facility":15,"status":7,"city":16,"state":7,"zip":17,"country":18,"countryCode":19,"cosmosGeoPoint":20,"geoPoint":25,"contacts":7},"Centre of Assisted Reproduction \"Embryoland\"","Athens","11 523","Greece","GR",{"type":21,"coordinates":22},"Point",[23,24],23.72784,37.98376,{"lat":24,"lon":23},{"type":27,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100147860","a-study-to-evaluate-the-baseline-follicle-stimulating-hormone-ovarian-volume-and-antral-follicle-count-as-prognostic-factors-of-the-outcome-of-in-vitro-fertilisationintracytosolic-sperm-injection-in-infertile-patients-receiving-gonal-f-for-controlled-ovarian-hyperstimulation-100147860",false,"NCT01196143","A Study to Evaluate the Baseline Follicle Stimulating Hormone, Ovarian Volume and Antral Follicle Count as Prognostic Factors of the Outcome of In-vitro Fertilisation\u002FIntracytosolic Sperm Injection in Infertile Patients Receiving Gonal f for Controlled Ovarian Hyperstimulation","Non-interventional Observational Study to Evaluate the Baseline FSH, Ovarian Volume and AFC (Antral Follicle Count) as Prognostic Factors of the Outcome of the In-vitro Fertilization\u002FIntracytosolic Sperm Injection (IVF\u002FICSI) in Infertile Patients Who Receive r-FSH (GONAL-f®) for Controlled Ovarian Hyperstimulation","Inclusion Criteria:\n\n* Pre-menopausal female subjects aged between 20-43 years\n* Subjects requiring treatment with recombinant FSH for COH for IVF and\u002For ICSI\n* Subjects who are able to communicate well with the investigator and can comply with the requirements of the entire study\n* Subjects who have given written informed consent, prior to treatment, with the understanding that consent may be withdrawn by the subject at any time without prejudice\n\nExclusion Criteria:\n\n* Female subjects not pregnant or lactating\n* Subjects with known allergic reaction against one of the ingredients\n* Subjects with enlarged ovaries or cysts unrelated to polycystic ovarian disease.\n* Subjects with gynaecological bleeding of unknown origin\n* Subjects with ovarian, uterine, or mammary cancer\n* Subjects with hyperprolactinaemia\n* Subjects with tumors of the hypothalamus or the pituitary gland","FEMALE","20 Years","43 Years",{"count":39,"type":40},356,"ACTUAL","OBSERVATIONAL","This is a phase IV non-interventional, multicentric observational study to evaluate the baseline follicle stimulating hormone (FSH) levels, ovarian volume, antral follicle count (AFC) and age as prognostic factors of the outcome of the in-vitro fertilisation\u002Fintracytosolic sperm injection (IVF\u002FICSI) in infertile subjects receiving Gonal-f for controlled ovarian hyperstimulation (COH).",[44],"Infertility",[46,47,48,49,50],"Ovulation induction","Intrauterine insemination","Gonal-f","Controlled ovarian stimulation","Female infertility","COMPLETED","2014-02-03",{"date":54,"type":55},"2014-02-04","ESTIMATED",{"date":57,"type":7},"2008-10",{"date":59,"type":40},"2011-01",{"name":5,"class":6},1]